Organ patterning in the adult stage: The role of Wnt/β-catenin signaling in liver zonation and beyond

Developmental Dynamics

Volumn 239, Issue 1, 2010, Pages 45-55

  Gebhardt, Rolf ^a   Hovhannisyan, Amalya ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Beta catenin; Differentiation; Hepatocellular carcinoma; Hepatocyte; Liver; Metabolic zonation; Patterning; Wnt

Indexed keywords

BETA CATENIN; HYPOXIA INDUCIBLE FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXO; WNT PROTEIN;

CANCER GROWTH; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE OVEREXPRESSION; HUMAN; LIVER DEVELOPMENT; LIVER PARENCHYMA; LIVER TUMOR; METABOLISM; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ZONATION;

ANIMALS; BETA CATENIN; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMANS; LIVER; LIVER NEOPLASMS; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; RECEPTOR CROSS-TALK; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; WNT PROTEINS;

EID: 73949116718     PISSN: 10588388     EISSN: 10970177     Source Type: Journal    
DOI: 10.1002/dvdy.22041     Document Type: Review

References (114)

1. Almeida M, Han L, Martin-Millan M, O'Brien CA, Manolagas SC. 2007. Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting betacatenin from T cell factor to forkhead box O-mediated transcription. J Biol Chem 282:27298-27305.
2. Alvarez-Medina R, Cayuso J, Okubo T, Takada S, Martl E. 2008. Wnt canonical pathway restricts graded Shh/Gli patterning activity through the regulation of Gli3 expression. Development 135:237-247.
3. Apte U, Zeng G, Muller P, Tan X, Micsenyi A, Cieply B, Dai C, Liu Y, Kaestner KH, Monga SP. 2006. Activation of Wnt/beta-catenin pathway during hepatocyte growth factor-induced hepatomegaly in mice. Hepatology 44:992-1002.
4. Arce L, Yokoyama NN, Waterman ML. 2006. Diversity of LEF/TCF action in development and disease. Oncogene 25:7492-7504.
5. Austinat M, Dunsch R, Wittekind C, Tannapfel A, Gebhardt R, Gaunitz F. 2008. Correlation between beta-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma. Mol Cancer 7:21-29.
6. Barolo S. 2006. Transgenic Wnt/TCF pathway reporters: all you need is Lef? Oncogene 25:7505-7511.
7. Barthel A, Schmoll D, Unterman TG. 2005. FoxO proteins in insulin action and metabolism. Tends Endocrin Metabol 16: 183-189.
8. Benhamouche S, Decaens T, Godard C, Chambrey R, Rickman DS, Moinard C, Vasseur-Cognet M, Kuo CJ, Kahn A, Perret C, Colnot S. 2006. Apc tumor suppressor gene is the "zonation-keeper" of mouse liver. Dev Cell 10:759-770.
9. Braeuning A, Ittrich C, Kohle C, Buchmann A, Schwarz M. 2007a. Zonal gene expression in mouse liver resembles expression patterns of Ha-ras and beta-catenin mutated hepatomas. Drug Metab Dispos 35: 503-507.
10. Braeuning A, Menzel M, Kleinschnitz EM, Harada N, Tamai Y, Köhle C, Buchmann A, Schwarz M. 2007b. Serum components and activated Ha-ras antagonize expression of perivenous marker genes stimulated by beta-catenin signaling in mouse hepatocytes. FEBS J 274:4766-4777.
11. Burke ZD, Tosh D. 2006. The Wnt/beta-catenin pathway: master regulator of liver zonation? Bioassays 28:1072-1077. Burke ZD, Thowfeequ S, Tosh D. 2006. Liver specification: a new role for Wnts in liver development. Curr Biol 16:688-690.
12. Cadoret A, Ovejero C, Saadi-Kheddouci S, Souil E, Fabre M, Romagnolo B, Kahn A, Perret C. 2001. Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin. Cancer Res 61:3245-3249.
13. Cadoret A, Ovejero C, Terris B, Souil E, Levy L, Lamers WH, Kitajewski J, Kahn A, Perret C. 2002. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 21:8293-8301.
14. Cavard C, Colnot S, Audard V, Benhamouche S, Finzi L, Torre C, Grimber G, Godard C, Terris B, Perret C. 2008. Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology. Future Oncol 4:647-660.
15. Colletti M, Cicchini C, Conigliaro A, Santangelo L, Alonzi T, Pasquini E, Tripodi M, Amicone L. 2009. Convergence of Wnt signaling on the HNF4-alpha-driven transcription in cintrolling liver zonation. Gastroenterology [Epub ahead of print].
16. Colnot S, Decaens T, Niwa-Kawakita M, Godard C, Hamard G, Kahn A, Giovannini M, Perret C. 2004. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci U S A 101:17216-17221.
17. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. 2008. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7:11-20.
18. Decaens T, Godard C, de Reyniès A, Rickman DS, Tronche F, Couty JP, Perret C, Colnot S. 2008. Stabilization of beta-catenin affects mouse embryonic liver growth and hepatoblast fate. Hepatology 47:247-258.
19. Easwaran V, Pishvaian M, Shah S, Byers SW. 1999. Cross-regulation of beta-catenin-LEF/TCF and retinoid signaling pathways. Curr Biol 9:1415-1418.
20. Ekataksin W, Kaneda K. 1999. Liver microvascular architecture: an insight into the pathophysiology of portal hypertension. Semin Liver Dis 19:359-382.
21. Essers MAG, Weijzen S, de Vries-Smits AM, Saarloos I, de Ruiter ND, Bos JL, Burgering BM. 2004. FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J 23:4802-4812.
22. Essers MAG, de Vries-Smits LMM, Barker N, Polderman PE, Burgering BMT, Korswagen HC. 2005. Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science 308:1181-1184.
23. Gebhardt R. 1992a. Metabolic zonation of the liver: implications for liver function and regulation. Pharmacol Ther 53:275-354.
24. Gebhardt R. 1992b. Cell-cell interactions: clues to hepatocyte heterogeneity and beyond? Hepatology 16:843-845.
25. Gebhardt R, Gaunitz F. 1997. Cell-cell-interactions in the regulation of the expression of hepatic enzymes. Cell Biol Toxicol 13:263-273.
26. Gebhardt R, Mecke D. 1983. Heterogeneous distribution of glutamine synthetase among rat liver parenchymal cells in situ and in primary culture. EMBO J 2:567-570.
27. Gebhardt R, Williams GM. 1995. Glutamine synthetase and hepatocarcinogenesis. Carcinogenesis 16:1673-1681.
28. Gebhardt R, Ueberham E. 2006. Zonal gene expression in murine liver: are tumors helping us to solve the mystery? Hepatology 44:512.
29. Gebhardt R, Cruise J, Houck KA, Luetteke NC, Novotny A, Thaler F, Michalopoulos G. 1986. Differential effect of growth factors on growth stimulation and phenotypic stability of glutamine-synthetasepositive and -negative hepatocytes in primary culture. Differentiation 33:45-55.
30. Gebhardt R, Tanaka T, Williams GM. 1989. Glutamine synthetase heterogeneous expression as a marker for the cellular lineage of preneoplastic and neoplastic liver populations. Carcinogenesis 10:1917-1923.
31. Gebhardt R, Gaunitz F, Mecke D. 1994. Heterogeneous (positional) expression of glutamine synthetase: features, regulation and implications for hepatocarcinogenesis. Adv Enzyme Regul 34:27-56.
32. Gebhardt R, Baldysiak-Figiel A, Krugel V, Ueberham E, Gaunitz F. 2007. Hepatocellular expression of glutamine synthetase: an indicator of morphogen actions as master regulators of zonation in adult liver. Prog Histochem Cytochem 41:201-266.
33. Gierer A, Meinhardt H. 1972. A theory of biological pattern formation. Kybernetic 12:30-39.
34. Goessling W, North TE, Lord AM, Ceol C, Lee S, Weidinger G, Bourque C, Strijbosch R, Haramis AP, Puder M, Clevers H, Moon RT, Zon LI. 2008. APC mutant zebrafish uncover a changing temporal requirement for wnt signaling in liver development. Dev Biol 320:161-174.
35. Grant SFA, Thorleifsson G, Reynisdottir I et al. 2006. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38:320-323.
36. Greer EL, Brunet A. 2005. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24:7410-7425.
37. Grisham JW. 1962. A morphologic study of deoxyribonucleic acid synthesis and cell proliferation in regenerating rat liver; autoradiography with thymidine-H3. Cancer Res 22:842-849.
38. Gross DN, van den Heuvel APJ, Birnbaum MJ. 2008. The role of FoxO in the regulation of metabolism. Oncogene 27:2320-2336.
39. Gupta RA, Dubois RN. 2002. Controversy: PPARgamma as a target for the treatment of colorectal cancer. Am J Physiol Gastrointest Liver Physiol 283:G266-G269.
40. Hailfinger S, Jaworski M, Braeuning A, Buchmann A, Schwarz M. 2006. Zonal gene expression in murine liver: lessons from tumors. Hepatology 43:407-414.
41. Han C, Lim K, Xu L, Li G, Wu T. 2008. Regulation of Wnt/beta-catenin pathway by cPLA2alpha and PPARdelta. J Cell Biochem 105:534-545.
42. Handeli S, Simon JA. 2008. A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities. Mol Cancer Ther 7:521-529.
43. Harada N, Miyoshi H, Murai N, Oshima H, Tamai Y, Oshima M, Taketo MM. 2002. Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. Cancer Res 62:1971-1977.
44. Harada N, Oshima H, Katoh M, Tamai Y, Oshima M, Taketo MM. 2004. Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Res 64:48-54.
45. He TC, Chan TA, Vogelstein B, Kinzler KW. 1999. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99:335-345.
46. Hoogeboom D, Burgering BM. 2009. Should I stay or should I go: beta-catenin decides under stress. Biochim Biophys Acta [Epub ahead of print].
47. Hoogeboom D, Essers MAG, Poldermann PE, Voets E, Smits LMM, Burgering BMTh. 2008. Interaction of FoxO with beta-catenin inhibits beta-catenin/T cell factor activity. J Biol Chem 283:9224-9230.
48. Hu M, Kurobe M, Jeong YJ, Fuerer C, Ghole S, Nusse R, Sylvester KG. 2007. Wnt/beta-catenin signaling in murine hepatic transit amplifying progenitor cells. Gastroenterology 133:1597-1591.
49. Hussain SZ, Sneddon T, Tan X, Micsenyi A, Michalopoulos GK, Monga SP. 2004. Wnt impacts growth and differentiation in ex vivo liver development. Exp Cell Res 292:157-169.
50. Imae M, Fu Z, Yoshida A, Noguchi T, Kato H. 2003. Nutritional and hormonal factors control the gene expression of FoxOs, the mammalian homologues of DAF-16. J Mol Endocrinol 30:253-262.
51. Jansson E, Are A, Greicius G, Kuo Ic, Kelly D, Arulampalam V, Petterson S. 2005. The Wnt/beta-catenin signaling pathway targets PPARgamma activity in colon cancer cells. Proc Natl Acad Sci U S A 102:1460-1465.
52. Jin T. 2008. The Wnt signaling pathway and diabetes mellitus. Diabetologia 51: 1771-1780.
53. Jin T, Fantus G, Sun J. 2008. Wnt and beyond Wnt: multiple mechanisms control the transcriptional property of betacatenin. Cell Signal 20:1697-1704.
54. Jungermann K. 1987. Metabolic zonation of liver parenchyma: significance for the regulation of glycogen metabolism, gluconeogenesis, and glycolysis. Diabetes Metab Rev 3:269-293.
55. Jungermann K, Kietzmann T. 2000. Oxygen: modulator of metabolic zonation and disease of the liver. Hepatology 31: 255-260.
56. Kaidi A, Williams AC, Paraskeva C. 2007. Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol 9:210-217.
57. Kestler HA, Kühl M. 2008. From individual Wnt pathways towards a Wnt signaling network. Philos Trans R Soc Lond B Biol Sci 363:1333-1347.
58. Kietzmann T, Dimova EY, Flügel D, Scharf JG. 2006. Oxygen: modulator of physiological and pathophysiological processes in the liver. Z Gastroenterol 44:67-76.
59. Lamers H, Hilberts A, Furt E, Smith J, Jonges GN, van Noorden CJF, Gaasbeek Janzen JW, Charles R, Moorman AFM. 1989. Hepatic enzymic zonation: a re-evaluation of the concept of the liver acinus. Hepatology 10:72-76.
60. Lenart J, Dombrowski F, Görlach A, Kietzmann T. 2007. Deficiency of manganese superoxide dismutase in hepatocytes disrupts gene expression in mouse liver. Arch Biochem Biophys 462:238-244.
61. Li H, Kim JH, Koh SS, Stallcup MR. 2004. Synergetic effects of coactivators GRIP1 and beta-catenin on gene activation: cross-talk between androgen receptor and Wnt signaling pathways. J Biol Chem 279:4212-4220.
62. Lim JH, Chun YS, Park JW. 2008. Hypoxia-inducible factor-1alpha obstructs a Wnt signaling pathway by inhibiting the hARD1-mediated activation of beta-catenin. Cancer Res 68:5177-5184.
63. Liu J, Farmer SR. 2004. Regulating the balance between peroxisome proliferators-activated receptor gamma and betacatenin signaling during adipogenesis. A glycogen synthase kinase 3beta phosphorylation-defective mutant of beta-catenin inhibits expression of a subset of adipogenic genes. J Biol Chem 279:45020-45027.
64. Liu J, Wang H, Zuo Y, Farmer SR. 2006. Functional interactions between peroxisome proliferator-activated receptor gamma and beta-catenin. Mol Cell Biol 26:5827-5837.
65. Loeppen S, Schneider D, Gaunitz F, Gebhardt R, Kurek R, Buchmann A, Schwarz M. 2002. Overexpression of glutamine synthetase is associated with beta-cateninmutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbital. Cancer Res 62:5685-5688.
66. Loeppen S, Koehle C, Buchmann A, Schwarz M. 2005. A beta-catenin- dependent pathway regulates expression of cytochrome P450 isoforms in mouse liver tumors. Carcinogenesis 26:239-248.
67. Manolagas SC, Almeida M. 2007. Gone with the Wnts: beta-catenin, T cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol 21:2605-2614.
68. Matsumoto K, Miki R, Nakayama M, Tatsumi N, Yokouchi Y. 2008. Wnt9a secreted from the walls of hepatic sinusoids is essential for morphogenesis, proliferation, and glycogen accumulation of chick hepatic epithelium. Dev Biol 319:234-247.
69. Mayer D, Buniatian G, Metzger Ch, Bannasch R, Gebhardt R. 1999. Dehydroepiandrosterone increases the zone of glutamine synthetase positive hepatocytes in female rat liver: a putative androgenic effect. Histochem Cell Biol 111:375-380.
70. Michalopoulos GK. 2007. Liver regeneration. J Cell Physiol 213:286-300.
71. Miyoshi Y, Iwao K, Nagasawa Y, Aihara T, Sasaki Y, Imaoka S, Murata M, Shimano T, Nakamura Y. 1998. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 58:2524-2527.
72. Monga SP, Pediaditakis P, Mule K, Stolz DB, Michalopoulos GK. 2001. Changes in Wnt/beta-catenin pathway during regulated growth in rat liver regeneration. Hepatology 33:1098-1109.
73. Monga SP, Mars WM, Pediaditakis P, Bell A, Mule K, Bowen WC, Wang X, Zarnegar R, Michalopoulos GK. 2002. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res 62:2064-2071.
74. Moriyama A, Kii I, Sunabori T, Kurihara S, Takayama I, Shimazaki M, Tanabe H, Oginuma M, Fukayama M, Matsuzaki Y, Saga Y, Kudo A. 2007. GFP transgenic mice reveal active canonical Wnt signal in neonatal brain and in adult liver and spleen. Genesis 45:90-100.
75. Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC. 2005. Interactions of nuclear receptors with the Wnt/beta-catenin/TCF signaling axis: Wnt you like to know? Endocr Rev 26:898-915.
76. Nakae J, Biggs III WH, Kitamura T, Cavenee WK, Wright CV, Arden KC, Accili D. 2002. Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat Genet 32:245-253.
77. Nateri AS, Spencer-Dene B, Behrens A. 2005. Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development. Nature 437:281-285.
78. Nejak-Bowen K, Monga SPS. 2008. Wnt/beta-catenin signaling in hepatic organogenesis. Organogenesis 4:92-99.
79. Neumann S, Coudreuse DYM, van der Westhuyzen DR, Eckhardt ERM, Korswagen HC, Schmitz G, Sprong H. 2009. Mammalian Wnt3a is released on lipoprotein particles. Traffic 10:334-343.
80. Nicholes K, Guillet S, Tomlinson E, Hillan K, Wright B, Frantz GD, Pham TA, Dillard-Telm L, Tsai SP, Stephan JP, Stinson J, Stewart T, French DM. 2002. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 160:2295-2307.
81. O'Brien RM, Noisin EL, Suwanickul A, Yamasaki T, Lucas PC, Wang JC, Powell DR, Granner DK. 1995. Hepatc nuclear factor 3- and hormone-regulated expression of the phosphoenolpyruvate carboxykinase and insulin-like growth-factor-binding protein 1 genes. Mol Cell Biol 15:1747-1758.
82. Oinonen T, Lindros KO. 1998. Zonation of hepatic cytochrome P450 expression and regulation. Biochem J 329:17-35.
83. Pawlowski JE, Ertel JR, Allen MP, Xu M, Butler C, Wilson EM, Wierman ME. 2002. Liganded androgen receptor interaction with beta-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells. J Biol Chem 277:20702-20710.
84. Rausa FM, Tan Y, Zhou H, Stolz DB, Watkins SC, Franks RR, Unterman TG, Costa RH. 2000. Elevated levels of hepatocyte nuclear factor 3beta in mouse hepatocytes influence expression of genes involved in bile acid and glucose homeostasis. Mol Cell Biol 20:8264-8282.
85. Reed KR, Athineos D, Meniel VS, Wilkins JA, Ridgway RA, Burke ZD, Muncan V, Clarke AR, Sansom OJ. 2008. B-catenin deficiency, but not Myc deletion, suppresses the immediate phenotypes of APC loss in the liver. Proc Natl Acad Sci U S A 105:18919-18923.
86. Roop D, Toftgard R. 2008. Hedgehog in Winterland. Nat Genet 40:1040-1041.
87. Ruijter JM, Gieling RG, Markman MM, Hagoort J, Lamers WH. 2004. Stereological maesurement of porto-central gradients in gene expression in mouse liver. Hepatology 39:343-352.
88. Sasse D, Spornitz UM, Maly IP. 1992. Liver architecture. Enzyme 46:8-32.
89. Schmoll D, Walker KS, Alessi DR, Grempler R, Burchell A, Guo S, Walther R, Unterman TG. 2000. Regulation of glucose-6-phosphatase gene expression by protein kinase Balpha and the forkhead transcription factor FKHR. Evidence for insulin response unit-dependent and -independent effects of insulin on promoter activity. J Biol Chem 275:36324-36333.
90. Sekine S, Lan BY, Bedolli M, Feng S, Hebrok M. 2006. Liver-specific loss of betacatenin blocks glutamine synthesis pathway activity and cytochrome p450 expression in mice. Hepatology 43:817-825.
91. Shackel N. 2007. Zebrafish and the understanding of liver development: the emerging role of the Wnt pathway in liver biology. Hepatology 45:540-541.
92. Shah S, Hecht A, Pestell R, Byers SW. 2003. Trans-repression of beta-catenin activity by nuclear receptors. J Biol Chem 278:48137-48145.
93. Shah S, Islam MN, Dakshanamurthy S, Rizvi I, Rao M, Herrell R, Zinser G, Valrance M, Aranda A, Moras D, Norman A, Welsh JE, Byers SW. 2006. The molecular basis of vitamin D receptor and beta-catenin crossregulation. Mol Cell 21:799-809.
94. Sick S, Reinker S, Timmer J, Schlake T. 2006. Wnt and DKK determine hair follicle spacing through a reaction-diffusion mechanism. Science 314:1447-1450.
95. Singh R, Artaza JN, Taylor WE, Braga M, Yuan X, Gonzalez-Cadavid NF, Bhasin S. 2006. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology 147:141-154.
96. Sirma H, Williams GM, Gebhardt R. 1996. Strain and sex-dependent variations in glutamine synthetase activity and distribution in rats and mice. Liver 16:166-173.
97. Spear BT, Jin L, Ramasamy S, Dobierzewska A. 2006. Transcriptional control in the mammalian liver: liver development, perinatal repression, and zonal gene regulation. Cell Mol Life Sci 63: 2922-2938.
98. Takigawa Y, Brown AM. 2008. Wnt signaling in liver cancer. Curr Drug Targets 9:1013-1024.
99. Tan X, Behari J, Cieply B, Michalopoulos GK, Monga SP. 2006. Conditional deletion of beta-catenin reveals its role in liver growth and regeneration. Gastroenterology 131:1561-1572.
100. Truica CI, Byers S, Gelmann EP. 2000. beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 60:4709-4713.
101. Turing A. 1952. The chemical basis of morphogenesis. Philos Trans R Soc Lond B Biol Sci 237:37-49.
102. Umemura T, Tokumo K, Sirma H, Gebhardt R, Poirier MC, Williams GM. 1993. Dose response effects of N-2-acetylaminofluorene on DNA damage, cytotoxicity, cell proliferation and neoplastic conversion in rat liver. Cancer Lett 73:1-10.
103. van den Brink GR, Bleuming SA, Hardwick JCH, Schepman BL, Offerhaus GJ, Keller JJ, Nielsen C, Gaffield W, van Deventer SJH, Roberts DJ, Peppelenbosch MP. 2004. Indian Hedgehog is an antagonist of Wnt signaling in colonic epithelial cell differentiation. Nat Genet 36:277-282.
104. Van der Vos KE, Coffer PJ. 2008. FOXO-binding partners: it takes two to tango. Oncogene 27:2289-2299.
105. Villacorta L, Garcia-Barrio MT, Chen YE. 2007. Transcriptional regulation of peroxisome proliferators-activated receptors and liver X receptor. Curr Atheroscler Rep 9:230-237.
106. Watt FM. 2004. Unexpected hedgehog-Wnt interactions in epithelial differentiation. Trends Mol Med 10:577-580.
107. Waxman DJ, O'Connor C. 2006. Growth hormone regulation of sex-dependent liver gene expression. Mol Endocrinol 20: 2613-2629.
108. Werth M, Gebhardt R, Gaunitz F. 2006. Hepatic expression of glutamine synthetase is controlled by STAT5 and TCF transcription factors. Hepatology 44:967-975.
109. Williams GM, Gebhardt R, Sirma H, Stenbäck F. 1993. Quantification of dose-related functional changes and neoplastic conversion in rat liver induced by low exposure to diethylnitrosamine. Carcinogenesis 14:2149-2156.
110. Willson TM, Brown PJ, Sternbach DD, Henke BR. 2000. The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527-550.
111. Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z. 2002. Linking beta-catenin to androgen-signaling pathway. J Biol Chem 277:11336-11344.
112. Yang SH, Andl T, Grachtchouk V, Wang A, Liu J, Syu LJ, Ferris J, Wang TS, Glick AB, Millar SE, Dlugosz AA. 2008. Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/β-catenin signaling. Nat Genet 40:1130-1134.
113. Zeng G, Awan F, Otruba W, Muller P, Apte U, Tan X, Gandhi C, Demetris AJ, Monga SP. 2007. Wnt'er in the liver: expression of Wnt and frizzled genes in mouse. Hepatology 45:195-204.
114. Zhang W, Patil S, Chauhan B, Guo S, Powell DR, Le J, Klotas A, Matika R, Xiao X, Franks R, Heidenreich KA, Sajan MP, Farese RV, Stolz DB, Tsa P, Koo SH, Montminy M, Unterman TG. 2006. FoxO1 regulates multiple metabolic pathways in the liver. Effects on gluconeogenic, glycolytic, and lipogenic gene expression. J Biol Chem 281:10105-10117.